Supplementary Information

Strategies for the Efficient Synthesis of Biheterocyclic 5-[2-(Trifluoromethylheteroaryl)-ethyl]-1,3,4-oxadiazoles from Levulinic Acid

Juliana L. Malavolta,^a Leandro M. Frigo,^b Sidnei Moura,^c Darlene C. Flores^d and Alex F. C. Flores^{*,d}

^aDepartamento de Química, Universidade Federal de Santa Maria, 97105-900 Santa Maria-RS, Brazil

^bInstituto Federal Farroupilha, 97420-000 São Vicente do Sul-RS, Brazil

^cInstituto de Biotecnologia, Universidade de Caxias do Sul, 95070-560 Caxias do Sul-RS, Brazil

^dEscola de Química e Alimentos, Universidade Federal de Rio Grande, 96203-900 Rio Grande-RS, Brazil

 1 H/ 13 C NMR spectra for the series of the 5(2)-[2-(trifluoromethyl heteroaryl)ethyl]-1,3,4-oxadiazoles are shown. The 1 H and 13 C (1D and 2D) spectra were recorded at 298 K on a Bruker DPX 400 spectrometer (1 H at 400.13 MHz, 13 C at 100.63 MHz) with digital resolution of ± 0.01 ppm. 0.1 M CDCl₃ or 0.1 M in DMSO- d_6 solutions were used, all the chemical shifts are expressed in ppm, with respect to internal TMS.



Figure S1. ¹H NMR spectrum (400 MHz, CDCl₃) of 2-[2-(5-trifluoromethyl-1*H*-pyrazol-3-yl)ethyl]-1,3,4-oxadiazole (4a).



Figure S2. ¹³C NMR spectrum (100 MHz, CDCl₃) of 2-[2-(5-trifluoromethyl-1*H*-pyrazol-3-yl)ethyl]-1,3,4-oxadiazole (4a).



Figure S3. ¹H NMR spectrum (400 MHz, CDCl₃) of 5-methyl-2-[2-(5-trifluoromethyl-1*H*-pyrazol-3-yl)ethyl]-1,3,4-oxadiazole (5a).



Figure S4. ¹³C NMR spectrum (400 MHz, CDCl₃) of 5-methyl-2-[2-(5-trifluoromethyl-1*H*-pyrazol-3-yl)ethyl]-1,3,4-oxadiazole (5a).



Figure S5. ¹H NMR spectrum (400 MHz, DMSO-*d*₆) of 5-phenyl-2-[2-(5-trifluoromethyl-1*H*-pyrazol-3-yl)ethyl]-1,3,4-oxadiazole (6a).



Figure S6. ¹³C NMR spectrum (100 MHz, DMSO-*d*₆) of 5-phenyl-2-[2-(5-trifluoromethyl-1*H*-pyrazol-3-yl)ethyl]-1,3,4-oxadiazole (6a).



Figure S7. ¹H NMR spectrum (400 MHz, CDCl₃) of 2-[2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl]-1,3,4-oxadiazole (4b).



Figure S8. ¹³C NMR spectrum (100 MHz, CDCl₃) of 2-[2-(2-phenyl-6-trifluormetilpyrimidin-4-yl)ethyl]-1,3,4-oxadiazol-2-yl (4b).



Figure S9. ¹H NMR spectrum (400 MHz, CDCl₃) of 5-methyl-2-[2-(2-phenyl-6-trifluoromethylpyrimidin4-yl)ethyl]-1,3,4-oxadiazole (**5b**).



Figure S10. ¹³C NMR spectrum (100 MHz, CDCl₃) of 5-methyl-2-[2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl]-1,3,4-oxadiazole (4b).



Figure S11. ¹H NMR spectrum (400 MHz, CDCl₃) of 2-phenyl-5-(2-(5-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl]-1,3,4-oxadiazole (6b).



Figure S12. ¹³C NMR spectrum (100 MHz, CDCl₃) of 5-phenyl-2-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)-ethyl)-1,3,4-oxadiazole (6b).



Figure S13. HMQC NMR spectrum (CDCl₃) of 5-phenyl-2-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)-ethyl)-1,3,4-oxadiazole (6b).



Figure S14. HMBC NMR spectrum (CDCl₃) of 5-phenyl-2-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)-ethyl)-1,3,4-oxadiazole (6b).



Figure S15. ¹H NMR spectrum (400 MHz, CDCl₃) of 2-[2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl]-1,3,4-oxadiazole (4c).



Figure S16. ¹³C NMR spectrum (100 MHz, CDCl₃) of 2-[2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl]-1,3,4-oxadiazole (4c).



Figure S17. ¹H NMR spectrum (400 MHz, CDCl₃) of 5-methyl-2-[2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl]1,3,4-oxadiazole (5c).



Figure S18. ¹³C NMR spectrum (400 MHz, CDCl₃) of 5-methyl-2-[2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl]1,3,4-oxadiazole (4c).



Figure S19. 2D-HMQC spectrum of 5-methyl-2-[2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl]1,3,4-oxadiazole (5c).



Figure S20. 2D-HMBC spectrum of 5-methyl-2-[2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl]1,3,4-oxadiazole (5c).



Figure S21. Expanded 2D-HMBC spectrum of 5-methyl-2-[2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl]1,3,4-oxadiazole (5c).



Figure S22. ¹H NMR spectrum (400 MHz, CDCl₃) of 5-phenyl-2-[2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl]1,3,4-oxadiazole (6c).



Figure S23. ¹³C NMR spectrum (100 MHz, CDCl₃) 5-phenyl-2-[2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl]1,3,4-oxadiazole (5c).



Figure S24. ¹³C DEPT135 NMR spectrum (100 MHz, CDCl₃) of 5-methyl-2-[2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl]1,3,4-oxadiazole (6c).



Figure S25. ¹H NMR spectrum (400 MHz, DMSO-*d*₆) of 2-[2-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl]-1,3,4-oxadiazole (4d).



Figure S26. Expanded ¹H NMR spectrum (400 MHz, DMSO-*d*₆) of 2-[2-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl]-1,3,4-oxadiazole (**4d**).

···



Figure S27. ¹³C NMR spectrum (400 MHz, DMSO-*d*₆) of 5-(2-(1,3,4-oxadiazol-2-yl)ethyl)-2-methyl-7-(trifluoromethyl)pyrazolo[1,5-*a*]pyrimidine (3d).



Figure S28. ¹³C DEPT 135 NMR spectrum (DMSO-*d*₆) of 2-[2-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl]-1,3,4-oxadiazole (4d).



Figure S29. ¹H NMR spectrum (400 MHz, DMSO-*d*₆) of 5-methyl-52-[2-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl]-1,3,4-oxadiazole (5d).



Figure S30. ¹³C NMR spectrum (400 MHz, DMSO- d_6) of 5-methyl-2-[2-(2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidin-5-yl)ethyl]-1,3,4-oxadiazole (4d).



Figure S31. 2D-HMQC NMR spectrum (DMSO-*d*₆) of 5-methyl-2-[2-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl]-1,3,4-oxadiazole (**5d**).



Figure S32. 2D-HMBC NMR spectrum (DMSO-*d*₆) of 5-methyl-2-[2-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl]-1,3,4-oxadiazole (5d).



Figure S33. Expanded HMBC NMR spectrum (DMSO- d_6) of 5-methyl-2-[2-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl]-1,3,4-oxadiazole (**5d**).



Figure S34. ¹H NMR spectrum (400 MHz, DMSO- d_6) of 5-phenyl-2-[2-(2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidin-5-yl)ethyl]-1,3,4-oxadiazole (6d).



Figure S35. ¹³C NMR spectrum (100 MHz, DMSO- d_6) of 5-phenyl-2-[2-(2-methyl-7-trifluoromethylpyrazolo[1,5-a]pyrimidin-5-yl)ethyl]-1,3,4-oxadiazole (6d).


Figure S36. ¹H NMR spectrum (400 MHz, DMSO-*d*₆) of 5-(2-(5-trifluoromethyl-1*H*-pyrazol-3-yl)ethyl)-1,3,4-oxadiazol-2-thiol (7a).



Figure S37. ¹³C NMR spectrum (100 MHz, DMSO-*d*₆) of 5-(2-(5-trifluoromethyl-1*H*-pyrazol-3-yl)ethyl)-1,3,4-oxadiazol-2-thiol (6a).



Figure S38. ¹H NMR spectrum (400 MHz, CDCl₃) of 5-[2-(thiomethyl-6-trifluormethylpyrimidin-4-yl)ethyl]-1,3,4-oxadiazol-2-thiol (7c).



Figure S39. ¹³C NMR spectrum (100 MHz, CDCl₃) of 5-(2-(thiomethyl-6-trifluormethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thiol (7c).



Figure S40. ¹H NMR spectrum (400 MHz, CDCl₃) of 5-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thiol (7b).



Figure S41. ¹³C NMR spectrum (100 MHz, CDCl₃) of 5-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thiol (7b).



Figure S42. ¹H NMR spectrum (400 MHz, DMSO-*d*₆) of 5(2-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl)-1,3,4-oxadiazol-2-thiol (7d).



Figure S43. ¹³C NMR spectrum (100 MHz, DMSO-*d*₆) of 5-[2-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl]-1,3,4-oxadiazol-2-thiol (7d).



Figure S44. ¹³C DEPT 135 NMR spectrum (DMSO-*d*₆) of 5-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl)-1,3,4-oxadiazol-2-thiol (7d).



Figure S45. ¹H NMR spectrum (400 MHz, CDCl₃) of 1-phenyl-2-[(5-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-yl)thio]ethanone or 2-[5-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl]acetophenone (**8b**).



Figure S46. ¹³C NMR spectrum (100 MHz, CDCl₃) of 1-phenyl-2-[(5-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-yl)thio]ethanone or 2-[5-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl]acetophenone (**8b**).



Figure S47. ¹³C DEPT135 NMR spectrum (100 MHz, CDCl₃) of 1-phenyl-2-[(5-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-yl)thio]ethanone or 2-[5-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl]acetophenone (**8b**).



Figure S48. ¹H NMR spectrum (400 MHz, CDCl₃) of 2-(5-(2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl) acetophenone (enol form, **8c**).



Figure S49. ¹³C NMR spectrum (100 MHz, CDCl₃) of 2-[(5-(2-(2-methylthio-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-yl)thio]-1-phenylethanone or 2-(5-(2-(2-thiomethylp-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl) acetophenone (**8c**).



Figure S50. 2D-HMQC NMR spectrum (CDCl₃) of 2-[(5-(2-(2-methylthio-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-yl)thio]-1-phenylethanone or 2-(5(2-(2-thiomethylporimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl) acetophenone (**8c**).



Figure S51. HMBC NMR spectrum of 2-[(5-(2-(2-methylthio-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-yl)thio]-1-phenylethanone or 2-(5-(2-(2-thiomethylperimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl) acetophenone (**8c**).



Figure S52. ¹H NMR spectrum (400 MHz, CDCl₃) of 5-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-yl ethanethioate (9b).



Figure S53. ¹³C NMR spectrum (100 MHz, CDCl₃) of 5-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl ethanethioate (9b).



Figure S54. ¹H NMR spectrum (400 MHz, CDCl₃) of 5-(2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl ethanethioate (9c).



Figure S55. ¹³C NMR spectrum (100 MHz, CDCl₃) of 5-(2-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl ethanethioate (9c).



Figure S56. ¹H NMR spectrum (400 MHz, DMSO- d_6) of 5-(2-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl)-1,3,4-oxadiazol-2-thioyl ethanethioate (**9d**).



Figure S57. ¹³C NMR spectrum (100 MHz, DMSO- d_6) of 5-(2-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)ethyl)-1,3,4-oxadiazol-2-thioyl ethanethioate (**9d**).



Figure S58. ¹H NMR spectrum (400 MHz, CDCl₃) of 5-(2-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl 2,2,2-trichloroethanethioate (10b).



Figure S59. ¹³C NMR spectrum (100 MHz, CDCl₃) of 5-(2-(2-phenil-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl 2,2,2-trichloroethanethioate (10b).



Figure S60. ¹H NMR spectrum (400 MHz, CDCl₃) of $5-(2-(2-\text{thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl 2,2,2-trichloroethanethioate ($ **10c**).



Figure S61. ¹³C NMR spectrum (100 MHz, CDCl₃) of $5-(2-(2-\text{thiomethyl-6-trifluoromethylpyrimidin-4-yl)ethyl)-1,3,4-oxadiazol-2-thioyl 2,2,2-trichloroethanethioate (10c).$



Figure S62. ¹H NMR spectrum (400 MHz, CDCl₃) of 3-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)-propanoylhydrazide 3b.



Figure S63. ¹³C NMR spectrum (100 MHz, CDCl₃) of 3-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)-propanoylhydrazide 3b.



Figure S64. ¹H NMR spectrum (400 MHz, CDCl₃) of 3-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)-propanoylhydrazide 3c.



Figure S65. ¹³C NMR spectrum (100 MHz, CDCl₃) of 3-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)-propanoylhydrazide 3c.



Figure S66. ¹H NMR spectrum (400 MHz, CDCl₃) 3-(2-methyl-7-trifluoromethylpirazolo[1,5-*a*]pirimidin-5-yl)propanoylhydrazide 3d.



Figure S67. ¹³C NMR spectrum (400 MHz, CDCl₃) of 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pirimidin-5-yl)propanoylhydrazide 3d.



Figure S68. ¹H NMR spectrum (400 MHz, CDCl₃) of N²-(2-chlorobenzylidene)-3-(2-phenyl-6-(trifluoromethyl)pyrimidin-4-yl)propanehydrazide 12b.



Figure S69. ¹³C NMR spectrum (400 MHz, CDCl₃) of N²-(2-chlorobenzylidene)-3-(2-phenyl-6-(trifluoromethyl)pyrimidin-4-yl)propanehydrazide 12b.



Figure S70. ¹H NMR spectrum (400 MHz, CDCl₃) of N'-(2-chlorobenzylidene)-3-(2-thiomethyl-6-(trifluoromethyl)pyrimidin-4-yl)propanehydrazide 12b.



Figure S71. ¹³C NMR spectrum (400 MHz, CDCl₃) of N'-(2-chlorobenzylidene)-3-(2-thiomethyl-6-(trifluoromethyl)pyrimidin-4-yl)propanehydrazide 12b.


Figure S72. ¹³C NMR spectrum (400 MHz, CDCl₃) of *N*'-(2-chlorobenzylidene)-3-(2-thiomethyl-6-(trifluoromethyl)pyrimidin-4-yl)propanehydrazide **12b**, expanded between 105-180 ppm.



Figure S73. ¹H NMR spectrum (400 MHz, CDCl₃) of ethyl 3-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)propanoate **13c**.



Figure S74. ¹³C NMR spectrum (400 MHz, CDCl₃) of ethyl 3-(2-thiomethyl-6-trifluoromethylpyrimidin-4-yl)propanoate 13c.



Figure S75. ¹H NMR spectrum (400 MHz, CDCl₃) of ethyl 3-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)propanoate 13b.



Figure S76. ¹³C NMR spectrum (400 MHz, CDCl₃) of ethyl 3-(2-phenyl-6-trifluoromethylpyrimidin-4-yl)propanoate 13b.



Figure S77. ¹H NMR spectrum (400 MHz, CDCl₃) of ethyl 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)-propanoate 13d.



Figure S78. ¹³C NMR spectrum (400 MHz, CDCl₃) of ethyl 3-(2-methyl-7-trifluoromethylpyrazolo[1,5-*a*]pyrimidin-5-yl)-propanoate 13d.